Models and methods of failure analysis and risk assessment during medical treatment

doi:10.3969/j.issn.2095-4344.2015.18.028

Abstract

Abstract:

BACKGROUND: Medical risks are all unsafe events or that damage to the patient during medical services. Present medical risk management is mainly qualitative experience, and lacks of regular failure analysis and risk assessment for established medical treatment.
OBJECTIVE: To construct models of medical process failure analysis and risk assessment, find possible risks during medical treatment, and propose effective measures to eliminate or decrease above risks.
METHODS: Failure mode and effects analysis during reliability engineering were used in production. That was, risk assessment was conducted in the possible technical failure modes, causes and all impacts on the product during each process. Improvement measures were made for weak link during the process. The risk could reach an acceptable level. In accordance with failure mode and effects analysis during production, the procedure of medical process failure analysis and risk assessment could be made to analyze the potential failures during medical treatment. Moreover, the improvement measures were proposed for weak link with high risks so as to prevent the occurrence of risk of significant adverse effects on patients.
RESULTS AND CONCLUSION: The methods and basic procedures of medical process failure analysis and risk assessment were established by using the experience of failure mode and effects analysis. Taking the rescue process of myocardial infarction in the emergency of a hospital as an example, the analysis of failures, reasons and impacts was performed taking “chewing 300 mg aspirin” in the rescue steps as a key. The improvement
measures and suggestions were proposed for unacceptable failures and reasons. Seen from the analysis results, proposed improvement measures and suggestions can obviously decrease the risks of failures caused by this step to patients. Therefore, the application of failure mode and effects analysis in medical treatment has a strong practical value.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Tissue Engineering, Risk Adjustment, Myocardial Infarction

CLC Number:

R318

Zhang Ying, Kang Rui . Models and methods of failure analysis and risk assessment during medical treatment[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(18): 2947-2852.

Figures/Tables 2

References

[1] 陈颖,康锐.FMECA技术及其应用(第2版)[M].北京:国防工业出版社,2014.
[2] 周功祥.FMEA质量理念及运用步骤[J].轻型汽车技术,2013,(10): 58-61.
[3] Chrysler LLC, Ford Motor Company, General Motors Corporation. “Potential failure mode and effects analysis (FMEA) Reference Manual Fourth Edition”. 2008.
[4] Kmenta S, Fitch P, Ishii K. Advanced failure modes and effects analysis of complex processes. Proceedings of the 1999 ASME design engineering technical conferences, DETC99/DFM-8939. 1999.
[5] Price CJ. Function-directed electrical design analysis. Artific Int Eng. 1998;12(4):445-456.
[6] Kimura F, Hata T, Kobayashi N. Reliability-Centered Maintenance Planning based on Computer-Aided FMEA, The 35th CIRP-International Seminar on Manufacturing Systems. 2002.
[7] Nannikar DN, Raut RM. FMEA for Manufacturing and Assembly Process. Int Conf Tech Business Management. 2012;(5):501-509.
[8] 曾成,韩依楠.PFMEA在SMT装配中的应用研究[J].绿色质量与管理,2009(8):44-51.
[9] 张炜,聂时南,邵旦兵.风险管理在急诊科的应用[J].医学研究生学报,2012,25(9):957-960.
[10] 陈敏,陈旭.医疗过程质量实时监控系统研究[J].中国医院管理, 2014,4(5):34-36.
[11] 许苹,孔令曼,秦婷,等.建立医疗风险预警机制的若干构想[J].中国卫生质量管理,2006,13(1):9-11.
[12] 许苹,秦婷,连斌,等.试论医疗风险预警体系构建[J].现代预防医学,2007,34(2):392-394.
[13] 吴宏,杨兴辰,连斌.医疗风险现状调查与分析研究[J].中国卫生质量管理,2009,16(4):2-4.
[14] 李升,黄玉珊.中国医疗风险预警机制的现状与初步评价[J].井冈山大学学报,2010,31(2):117-120.
[15] 王东红.中国医疗风险预警研究现状分析与展望[J].中国卫生质量管理,2014,2(21):28-30.
[16] 郝璐,陈黎明,健康管理现状与发展思考[J].解放军医院管理杂志, 2014,2(26):158-160.
[17] 杨克虎,马彬.美国医疗风险监测预警机制现状及绩效的循证评价[J].中国循证医学杂志,2006(6):439-450.
[18] 毕桂泉,王再岭.医院加强医疗风险管理初探[J].解放军医院管理杂志,2014,2(15):144-145.
[19] 孙楠,黎爱军.医疗风险影响因素调查分析和对策研究[J].中国卫生质量管理,2009,16(4):5-7.
[20] Matthew Grissinger. Failure mode and effects analysis can help guide error-prevention efforts. Med Error. 2003; 28(1): 8.
[21] Chadwick L, Fallon EF. Evaluation and critique of healthcare failure mode and effect analysis applied in a radiotherapy case study. Human Factors and Ergonomics in Manufacturing Service Industries. 2013;23(2):116-127.
[22] Christina N, Cote J, Lebel D. The AMELIE project: failure mode, effects and criticality analysis: a model to evaluate the nurse medication administration process on the floor. J Eval Clin Prac. 2013;19(1):192-199.
[23] 许苹,许敏,刑茂迎,等.FMEA在医疗风险管理中的应用以及局限性[J].现代预防医学,2007,34(1):51-52.
[24] 李洋,杜蕾.FMEA法在医疗风险管理中的应用现状与展望[J].中国医院管理,2014,9(35):36-37.
[25] 潘黎,潘小炎.中国医疗失效模式与效应分析的应用现状及问题[J].医学与哲学(B),2014,6(35):89-93.
[26] 曹松美.失效模式与效应分析在住院患者静脉用药管理中的应用[J].中国误诊学杂志,2012,12(7):1611-1612.
[27] 黄春燕.刘霜梅.吴晓静,等.医疗失效模式与效应分析在老年患者跌倒风险中的应用[J].护士进修杂志,2013,28(3):256-258.
[28] 赖翠薇.应用FMEA改进高血压脑出血患者的护理方法[J].临床医学工程,2012,19(12):2226-2227.
[29] 周小桥.过程失效模式及后果分析:制定项目风险管理计划的有效工具[J].项目管理技术,2004,(5):32-36.
[30] 王竹,刘胧,马帅.医疗设备使用风险评估中的FMECA新方法[J].工业工程,2012,15(2):11-16.
[31] 王文旭.FMEA技术在危险源辨识、风险评价、风险控制策划中的应用[J].中国质量认证,2004,(8):49-51.
[32] Bukofzer S, Ayres J, Chavez A, et al. Industry perspective on the medical risk of visible particles in injectable drug products. PDA J Pharm Sci Technol. 2015;69(1):123-139.
[33] Satasivam P, Reeves F, Rao K, et al. Patients with medical risk factors for chronic kidney disease are at increased risk of renal impairment despite the use of nephron-sparing surgery. BJU Int. 2015. doi: 10.1111/bju.13075.
[34] Tonning Olsson I, Perrin S, Lundgren J, et al. Long-term cognitive sequelae after pediatric brain tumor related to medical risk factors, age, and sex. Pediatr Neurol. 2014;51(4): 515-521.
[35] Gaston RS, Kumar V, Matas AJ. Reassessing Medical Risk in Living Kidney Donors. J Am Soc Nephrol. 2014.
[36] Spangler EL, Goodney PP, Schanzer A, et al. Outcomes of carotid endarterectomy versus stenting in comparable medical risk patients. J Vasc Surg. 2014;60(5):1227-1231.
[37] Stoff BK, Swerlick RA. Reframing risk part II: Methods for improving medical risk communication. J Am Acad Dermatol. 2013;69(4):637-639.
[38] Stoff BK, Cruze D, Swerlick RA. Reframing risk part I: Legal and ethical standards for medical risk disclosure. J Am Acad Dermatol. 2013;69(4):634-636.
[39] Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One. 2013;8(7):e69981.
[40] Izadi N, Malek M, Aminian O, et al. Medical risk factors of diabetes mellitus among professional drivers. J Diabetes Metab Disord. 2013;12(1):23.
[41] Alhadad A, Wictorsson C, Alhadad H, et al. Medical risk factor treatment in peripheral arterial disease. Need for further improvement. Int Angiol. 2013;32(3):332-338.
[42] Altamash M, Arledal S, Klinge B, et al. Pre-diabetes and diabetes: Medical risk factors and periodontal conditions. Acta Odontol Scand. 2013;71(6):1625-1631.
[43] Sudzinova A, Nagyova I, Studencan M, et al. Roma coronary heart disease patients have more medical risk factors and greater severity of coronary heart disease than non-Roma. Int J Public Health. 2013;58(3):409-415.
[44] Brand HS. Reaction to European medical risk registered case history system. Ned Tijdschr Tandheelkd. 2013;120(2):56.
[45] Abraham-Inpijn L. European medical risk registered case history system. Ned Tijdschr Tandheelkd. 2013;120(2):56.
[46] Brand H. Dentists should apply the european medical risk registered history taking system to every patient. Ned Tijdschr Tandheelkd. 2012;119(9):409.
[47] Gortzak R. Dentists should apply the European Medical Risk Registered History Taking System to every patient. Ned Tijdschr Tandheelkd. 2012;119(9):408.
[48] Lindsey NP, Staples JE, Lehman JA, et al. Medical risk factors for severe west nile virus disease, United States, 2008-2010. Am J Trop Med Hyg. 2012;87(1):179-184.
[49] Treyvaud K, Inder TE, Lee KJ, et al. Can the home environment promote resilience for children born very preterm in the context of social and medical risk? J Exp Child Psychol. 2012;112(3):326-337.
[50] Lundequist A, Böhm B, Smedler AC. Individual neuropsychological profiles at age 5½ years in children born preterm in relation to medical risk factors. Child Neuropsychol. 2013;19(3):313-331.
[51] Kraemer R, Wuerfel W, Lorenzen J, et al. Analysis of hereditary and medical risk factors in Achilles tendinopathy and Achilles tendon ruptures: a matched pair analysis. Arch Orthop Trauma Surg. 2012;132(6):847-853.